公开(公告)号：EP2181103B1

公开(公告)日：2015-08-05

申请号：EP07844994.9

申请日：2007-11-08

申请人： The Board Of Trustees Of The University Of Illinois

发明人： GILLIS, Eric, P. ,  LEE, Suk, Joong ,  GRAY, Kaitlyn ,  BURKE, Martin, D. ,  KNAPP, David, M.

IPC分类号： C07D307/80 ,  C07F5/02

CPC分类号： C07F5/025 ,  C07C45/68 ,  C07C51/353 ,  C07C67/343 ,  C07D213/55 ,  C07D307/81 ,  C07F5/02 ,  C07F5/04 ,  Y02P20/55

摘要： A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.

公开(公告)号：EP2795627A1

公开(公告)日：2014-10-29

申请号：EP12859006.4

申请日：2012-12-20

申请人： The Board of Trustees of the University of Illinois

发明人： WALKER, Steven, B. ,  LEWIS, Jennifer, A.

IPC分类号： H01B1/22

CPC分类号： C09D11/52 ,  B05D1/005 ,  B05D1/04 ,  B05D1/18 ,  C23C18/161 ,  C23C18/168 ,  C23C18/1692 ,  C23C18/42 ,  C23C18/44 ,  C23C26/02

摘要： An ink composition for making a conductive silver structure comprises a silver salt and a complex of (a) a complexing agent and a short chain carboxylic acid or (b) a complexing agent and a salt of a short chain carboxylic acid, according to one embodiment. A method for making a silver structure entails combining a silver salt and a complexing agent, and then adding a short chain carboxylic acid or a salt of the short chain carboxylic acid to the combined silver salt and a complexing agent to form an ink composition. A concentration of the complexing agent in the ink composition is reduced to form a concentrated formulation, and the silver salt is reduced to form a conductive silver structure, where the concentrated formulation and the conductive silver structure are formed at a temperature of about 120° C. or less.

公开(公告)号：EP2764370A2

公开(公告)日：2014-08-13

申请号：EP12778001.3

申请日：2012-10-06

申请人： The Board of Trustees of the University of Illinois ,  The United States Government as represented by The Department of Veterans Affairs

发明人： DUDLEY, Samuel ,  SOLARO, Ross, John ,  JEONG, Euy-Myoung

IPC分类号： G01N33/68

CPC分类号： G01N33/6887 ,  A61K38/4866 ,  C12Y304/21069 ,  G01N2333/4712 ,  G01N2500/00 ,  G01N2800/325 ,  G01N2800/54

摘要： The present disclosures provide methods relating to the diagnosis and treatment of diastolic heart failure.

摘要翻译： 本披露提供与舒张性心脏衰竭的诊断和治疗方法。

公开(公告)号：EP2078222B1

公开(公告)日：2014-06-18

申请号：EP07799443.2

申请日：2007-07-10

申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

发明人： RALSTON, Tyler, S. ,  MARKS, Daniel, L. ,  CARNEY, Paul, Scott ,  BOPPART, Stephen, A.

IPC分类号： G02B21/36 ,  G01N21/47 ,  G02B21/00 ,  G02B27/58

CPC分类号： G02B21/0056 ,  G01N21/4795 ,  G02B21/0064 ,  G02B27/58

公开(公告)号：EP2389391B1

公开(公告)日：2014-03-12

申请号：EP10702081.0

申请日：2010-01-22

申请人： Centre National de la Recherche Scientifique CNRS ,  The Board Of Trustees Of The University Of Illinois ,  Université de Strasbourg

发明人： METZGER, Daniel ,  CHAMBON, Pierre ,  ZHAO, Huimin ,  KATZENELLENBOGEN, John

IPC分类号： C07K14/72 ,  C12N9/00 ,  C12N15/90 ,  C12N9/90

CPC分类号： C07K14/721 ,  C07K2319/715 ,  C12N9/90

公开(公告)号：EP2659884A2

公开(公告)日：2013-11-06

申请号：EP13166145.6

申请日：2006-05-26

申请人： The Board of Trustees of the University of Illinois

发明人： Hergenrother, Paul J. ,  Putt, Karson S ,  Chen, Grace W. ,  Pearson, Jennifer M.

IPC分类号： A61K31/00 ,  A61K31/495 ,  C07D295/15 ,  A61P35/00 ,  C12Q1/37 ,  G01N33/50

CPC分类号： A61K31/495 ,  C07D295/15 ,  C12Q1/37 ,  G01N33/502 ,  G01N33/574 ,  G01N2333/96466 ,  G01N2510/00 ,  G01N2800/52

摘要： Compounds and related methods for synthesis, and the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3, and particular embodiments are capable of direct activation of procaspase-3 and procaspase-7 to the effector forms of caspase-3 and caspase-7. Procaspase-3 levels can vary among cancer cell types; several types have relatively high levels and can have increased susceptibility to chemotherapy by compounds and methods herein. Therapeutic applications are relevant for a variety of cancer conditions and cell types, e.g. breast, lung, brain, colon, renal, adrenal, melanoma, and others.

摘要翻译： 公开了合成的化合物和相关方法，以及化合物在治疗中用于治疗癌症和选择性诱导细胞凋亡的用途。 公开了关于胱天蛋白酶例如胱天蛋白酶-3修饰的化合物，特定实施方案能够将胱天蛋白酶-3和胱天蛋白酶-7的效应物形式直接活化胱天蛋白酶-3和胱天蛋白酶原-7。 Procaspase-3水平可以在癌细胞类型之间变化; 几种类型具有相对较高的水平，并且可以通过本文化合物和方法增加对化学疗法的易感性。 治疗应用与各种癌症状况和细胞类型相关，例如， 乳腺，肺，脑，结肠，肾，肾上腺，黑素瘤等。

公开(公告)号：EP2638393A2

公开(公告)日：2013-09-18

申请号：EP11839117.6

申请日：2011-11-09

申请人： The General Hospital Corporation ,  Massachusetts Institute of Technology ,  The Board of Trustees of the University of Illinois ,  Daktari Diagnostics, Inc.

发明人： WATKINS, Nicholas ,  BASHIR, Rashid ,  RODRIGUEZ, William ,  CHENG, Xuanhong ,  TONER, Mehmet ,  CHEN, Grace ,  OPPENHEIMER, Aaron

IPC分类号： G01N33/53 ,  G01N33/52 ,  G01N21/17 ,  C12M1/34

CPC分类号： G01N27/02 ,  B01L2200/0652 ,  B01L2300/0877 ,  C12M41/36 ,  G01N15/12 ,  G01N15/1245 ,  G01N33/56972 ,  G01N2015/1006 ,  G01N2015/1486

摘要： This disclosure relates to methods and devices to count particles of interest, such as cells. The methods include obtaining a fluid sample that may contain particles of interest; counting all types of particles in a portion of the sample using a first electrical differential counter to generate a first total; removing any particles of interest from the portion of the fluid sample; counting any particles remaining in the portion of the fluid sample using a second electrical differential counter after the particles of interest are removed to generate a second total; and calculating a number of particles of interest originally in the fluid sample by subtracting the second total from the first total, wherein the difference is the number of particles of interest in the sample. These methods and related devices can be used, for example, to produce a robust, inexpensive diagnostic kit for CD4+ T cell counting in whole blood samples.

公开(公告)号：EP2606048A1

公开(公告)日：2013-06-26

申请号：EP11818823.4

申请日：2011-08-19

申请人： The Board of Trustees of the University of Illinois

发明人： HARTWIG, John, F. ,  MORIMOTO, Hiroyuki ,  FIER, Patrick

IPC分类号： C07D471/04

CPC分类号： C07C17/32 ,  B01J31/0231 ,  B01J31/0235 ,  B01J31/0244 ,  C07B39/00 ,  C07C17/263 ,  C07C22/08 ,  C07C29/32 ,  C07C37/11 ,  C07C41/30 ,  C07C41/48 ,  C07C45/63 ,  C07C45/68 ,  C07C67/293 ,  C07C67/343 ,  C07C201/12 ,  C07C209/68 ,  C07C231/12 ,  C07C253/30 ,  C07D209/08 ,  C07D209/10 ,  C07D213/26 ,  C07D213/61 ,  C07D215/12 ,  C07D215/18 ,  C07D239/22 ,  C07D239/54 ,  C07F1/08 ,  C07C43/225 ,  C07C33/46 ,  C07C47/55 ,  C07C49/80 ,  C07C69/63 ,  C07C43/1742 ,  C07C69/76 ,  C07C43/313 ,  C07C255/50 ,  C07C25/13 ,  C07C205/11 ,  C07C211/52 ,  C07C233/15

摘要： A method of forming a fluorinated molecular entity includes reacting in a reaction mixture an aromatic halide, copper, a fluoroalkyl group, and a ligand. The aromatic halide includes an aromatic group and a halogen substituent bonded to the aromatic group. The ligand includes at least one group-V donor selected from phosphorus and an amine. The overall molar ratio of copper to aromatic halide in the reaction mixture is from 0.2 to 3. The method further includes forming a fluoroalkylarene including the aromatic group and the fluoroalkyl group bonded to the aromatic group. A composition, which may be used in the method, consists essentially of copper, the fluoroalkyl group, and the ligand, where the molar ratio of copper to the fluoroalkyl group is approximately 1.

摘要翻译： 形成氟化分子实体的方法包括在反应混合物中使芳族卤化物，铜，氟代烷基和配体反应。 芳族卤化物包括芳族基团和与芳族基团键合的卤素取代基。 该配体包括至少一个选自磷和胺的V族供体。 反应混合物中铜与芳族卤化物的总摩尔比为0.2至3.所述方法还包括形成包含与芳族基团键合的芳族基团和氟烷基的氟烷基芘。 可用于该方法中的组合物基本上由铜，氟烷基和配体组成，其中铜与氟烷基的摩尔比约为1。

公开(公告)号：EP2327086B1

公开(公告)日：2013-06-12

申请号：EP09820978.6

申请日：2009-09-23

申请人： The Board of Trustees of the University of Illinois

发明人： EDEN, J., Gary ,  PARK, Sung-Jin ,  SUNG, Seung, Hoon

IPC分类号： H01J65/04 ,  H01J9/24 ,  H01J11/18

CPC分类号： H01J65/046 ,  H01J9/241 ,  H01J11/18

公开(公告)号：EP2598881A2

公开(公告)日：2013-06-05

申请号：EP11813253.9

申请日：2011-07-29

申请人： The Board of Trustees of the University of Illinois

发明人： DUDLEY, Samuel ,  NEGI, Smita

IPC分类号： G01N33/53

CPC分类号： G01N33/6893 ,  G01N33/6896 ,  G01N2333/4737 ,  G01N2800/2871 ,  G01N2800/52 ,  G01N2800/7009

摘要： The invention provides methods of determining risk for stroke in a patient, as well as methods of determining a subject's need for anti-coagulation therapy. In exemplary embodiments, the method comprises measuring a level of derivatives of reactive oxygen metabolites (DROMs) in a biological sample obtained from the subject, wherein an increased level of DROMs, relative to a control level, is indicative of the subject's need for anticoagulation therapy. Further provided are methods of decreasing risk of stroke in a subject, methods of determining the efficacy of a therapeutic agent, methods of monitoring a subject's risk of stroke, and kits.